$MDXG earnings report

Third-quarter net sales declined 45% as Wound sales fell 71%, while Surgical sales increased 9%, gross margin improved sequentially to 80%, and Adjusted EBITDA returned to positive $2,066 (in thousands). AlphAI read Mimedx Group's Third quarter 2026 filing as mixed. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readMDXG · Third quarter 2026 · ended September 30, 2026

Third-quarter net sales declined 45% as Wound sales fell 71%, while Surgical sales increased 9%, gross margin improved sequentially to 80%, and Adjusted EBITDA returned to positive $2,066 (in thousands).

→Mixed quarter

Surgical sales increased 9% and the company returned to positive Adjusted EBITDA, supported by cost actions and sequential gross-margin improvement. However, total net sales declined 45%, Wound sales declined 71%, GAAP net income turned to a loss, and nine-month operating cash flow was negative.

Revenue
$62.3M
decrease of 45% y/y
Surgical, three months ended September 30, 2026
$40.0M
increased 9% y/y
Gross margin · GAAP
80%
EPS · non-GAAP
(0.01)
2026, fourth quarter 2026 and longer-term outlook
2026 net sales of $250 to $260 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$62.28M–decrease of 45%
Cost of sales, three months ended September 30, 2026GAAP$12.58M––
Gross profit, three months ended September 30, 2026GAAP$49.70M––
Gross margin, three months ended September 30, 2026GAAP80%––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$58.31M––
Research and development expenses, three months ended September 30, 2026GAAP$2.80M––
Amortization of intangible assets, three months ended September 30, 2026GAAP$295K––
Operating loss, three months ended September 30, 2026GAAP−$11.70M––
Interest income, net, three months ended September 30, 2026GAAP$776K––
Other expense, net, three months ended September 30, 2026GAAP−$136K––
Loss before income tax, three months ended September 30, 2026GAAP−$11.06M––
Income tax benefit, three months ended September 30, 2026GAAP$2.38M––
Net loss, three months ended September 30, 2026GAAP−$8.68M––
Basic net loss per common share, three months ended September 30, 2026GAAP$(0.06)––
Diluted net loss per common share, three months ended September 30, 2026GAAP$(0.06)––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$2.07M––
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP3.3 %––
Adjusted net loss, three months ended September 30, 2026non-GAAP−$718K––
Adjusted Earnings Per Share, three months ended September 30, 2026non-GAAP(0.01)––
Net cash flows provided by operating activities, three months ended September 30, 2026GAAP$3.92M––
Capital expenditures, including purchases of equipment, three months ended September 30, 2026GAAP−$166K––
Free Cash Flow, three months ended September 30, 2026non-GAAP$3.75M––
Net sales, nine months ended September 30, 2026GAAP$185.6M––
Gross profit, nine months ended September 30, 2026GAAP$135.7M––
Selling, general and administrative expenses, nine months ended September 30, 2026GAAP$171.3M––
Research and development expenses, nine months ended September 30, 2026GAAP$9.71M––
Operating loss, nine months ended September 30, 2026GAAP−$46.22M––
Net loss, nine months ended September 30, 2026GAAP−$34.38M––
Diluted net loss per common share, nine months ended September 30, 2026GAAP$(0.23)––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP−$17.62M––
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP(9.5) %––
Adjusted net loss, nine months ended September 30, 2026non-GAAP−$14.76M––
Adjusted Earnings Per Share, nine months ended September 30, 2026non-GAAP(0.10)––
Net cash flows used in operating activities, nine months ended September 30, 2026GAAP−$4.22M––
Free Cash Flow, nine months ended September 30, 2026non-GAAP−$5.55M––

Segments

SegmentRevenueq/qy/y
Surgical, three months ended September 30, 2026Led by sales of AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®; management said Surgical product volume delivered mid-teens growth.$39.96M–increased 9%
Wound, three months ended September 30, 2026Negatively impacted by several Medicare reimbursement changes that went into effect on January 1, 2026; sales to Wound Care Centers continued to grow sequentially and unit volume grew 7% sequentially.$22.32M–decrease of 71%
Surgical, nine months ended September 30, 2026Product-category net sales reported for the nine months ended September 30, 2026.$115.6M––
Wound, nine months ended September 30, 2026Product-category net sales reported for the nine months ended September 30, 2026.$70.00M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026, fourth quarter 2026 and longer-term outlook

  • Revenue2026 net sales of $250 to $260 million
  • NoteAdjusted EBITDA for the fourth quarter to be sequentially higher than the third quarter.
  • NoteLonger-term annual net sales growth in the low double-digits as a percentage.
  • NoteLonger-term adjusted EBITDA margin above 20%.

What drove it

  • Surgical sales increased 9% year over year, led by AMNIOFIX®, AMNIOEFFECT® and HELIOGEN® sales.
  • Management cited mid-teens Surgical volume growth against a strong prior-year comparison and softer U.S. surgical procedure volumes.
  • Cost actions announced in April and lower commissions on lower sales reduced SG&A expense.
  • Gross-margin improvement from 69% last quarter to 80% was attributed to cost removal and manufacturing efficiencies.
  • The U.S. District Court for the Northern District of Georgia vacated FDA determinations regarding AXIOFILL and remanded both matters to FDA for further consideration consistent with its order.

Concerns

  • Wound sales decreased 71% year over year, and management said Medicare reimbursement changes effective January 1, 2026 continued to negatively impact the Wound business.
  • Total net sales decreased 45% year over year and GAAP net income changed from $16,748 (in thousands) to a net loss of $(8,683) (in thousands).
  • Gross margin was below the prior-year 84%, with the decline attributed primarily to Medicare reimbursement rules affecting Wound product prices and unfavorable product mix.
  • SG&A included $6 million of incremental legal and strategic expenses associated with ongoing litigation matters and transaction costs related to the proposed Sanara acquisition.
  • The proposed Sanara acquisition remains subject to HSR clearance, and the filing identifies FTC review, financing availability, ticking fees, termination fees, integration risks, and potential unrealized synergies as risks.

What to watch

  • Whether fourth-quarter Adjusted EBITDA is sequentially higher than the third quarter, as guided.
  • Wound Care Center sales and unit-volume trends as the Wound Care market works through the reimbursement reset.
  • Surgical sales and volume growth, including sales of AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®.
  • The outcome of FDA's further consideration of AXIOFILL following the court remand.
  • Progress toward HSR clearance and completion of the proposed Sanara acquisition.
  • Receipt of the four remaining annual $5 million patent-license installments.

Balance sheet and cash flow

  • Cash and cash equivalents were $120,791 (in thousands) as of September 30, 2026, compared to $166,121 (in thousands) as of December 31, 2025.
  • Net cash increased $2 million compared to the second quarter 2026.
  • The Company repaid the remaining $17 million term loan balance and ended the quarter with no debt outstanding.
  • Total assets were $264,552 (in thousands) as of September 30, 2026, compared to $342,653 (in thousands) as of December 31, 2025.
  • Total liabilities were $53,470 (in thousands) as of September 30, 2026, compared to $86,105 (in thousands) as of December 31, 2025.
  • Net cash flows used in investing activities were $(6,470) (in thousands) for the nine months ended September 30, 2026, compared to $(6,551) (in thousands) in the prior-year period.
  • Net cash flows used in financing activities were $(34,643) (in thousands) for the nine months ended September 30, 2026, compared to $(4,829) (in thousands) in the prior-year period.
  • Net change in cash was $(45,330) (in thousands) for the nine months ended September 30, 2026, compared to $37,667 (in thousands) in the prior-year period.
  • A patent licensee will pay MIMEDX a total of $25 million in five equal installments of $5 million; the first installment has been received and four remaining installments will be paid annually on the anniversary of the signing date.

Analysis

MIMEDX reported third-quarter net sales of $62,283 (in thousands), down 45% from $113,725 (in thousands). The result reflected sharply divergent franchise performance. Surgical sales increased 9% to $39,960 (in thousands), led by AMNIOFIX®, AMNIOEFFECT® and HELIOGEN®, while Wound sales decreased 71% to $22,323 (in thousands). Management described Surgical as nearly two-thirds of net sales and cited mid-teens Surgical volume growth despite softer U.S. surgical procedure volumes.

The Wound business remained the principal drag. Management attributed the decline to several Medicare reimbursement changes effective January 1, 2026, which affected Wound product pricing and added pressure to mix. It nevertheless reported sequential sales growth to Wound Care Centers and 7% sequential growth in Wound Care Center unit volume. This developing migration into Wound Care Centers is central to the company's stated view that the market is beginning to adjust.

Profitability improved sequentially but remained substantially below the prior-year period. Gross margin was 80%, up from 69% last quarter, but below 84% a year earlier. MIMEDX attributed the sequential improvement to cost removal and manufacturing efficiencies, whereas the year-over-year decline reflected reimbursement-related Wound pricing pressure and unfavorable product mix. SG&A declined to $58,313 (in thousands) from $69,001 (in thousands), supported by the April cost-reduction initiative and lower commissions, although it included $6 million of incremental legal and strategic expenses.

GAAP net loss was $(8,683) (in thousands), compared with net income of $16,748 (in thousands) a year earlier. Adjusted EBITDA was positive at $2,066 (in thousands), compared with $34,950 (in thousands), and adjusted EBITDA margin was 3.3 % compared with 30.7 %. Quarterly operating cash flow was $3,919 (in thousands) and Free Cash Flow was $3,753 (in thousands), while nine-month operating cash flow and Free Cash Flow were $(4,217) (in thousands) and $(5,551) (in thousands), respectively.

The company ended the quarter with $120,791 (in thousands) of cash and cash equivalents, repaid its remaining $17 million term loan balance, and had no debt outstanding. It now expects 2026 net sales of $250 to $260 million and expects fourth-quarter Adjusted EBITDA to be sequentially higher than the third quarter. Longer term, it continues to target low double-digit annual net sales growth and adjusted EBITDA margin above 20%. The filing also highlighted the AXIOFILL court ruling, a $25 million patent-license agreement, and the unresolved HSR review for the proposed Sanara acquisition.

Management, verbatim

Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.

Joseph H. Capper, MIMEDX Chief Executive Officer

As the Wound Care market works through a sluggish reset, we are beginning to see the anticipated signs of adjustment, including patient migration into Wound Care Centers, where MIMEDX unit volume grew 7% sequentially in the quarter.

Joseph H. Capper, MIMEDX Chief Executive Officer

We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.

Joseph H. Capper, MIMEDX Chief Executive Officer

Not in the filing

stated, not guessed
  • No dividend or share-repurchase activity was reported.
  • No fourth-quarter 2026 revenue range, gross-margin guidance, operating-expense guidance, or tax-rate guidance was reported.
  • No quarterly sequential net-sales comparison was reported for total net sales, Surgical sales, or Wound sales.
  • No GAAP operating cash flow, Free Cash Flow, or capital expenditure figures were reported for the immediately preceding quarter.
  • No standalone third-quarter Adjusted Gross Profit, Adjusted Gross Margin, or adjusted R&D expense comparison was reported in the primary non-GAAP summary tables.
  • The previous outlook covered the full year 2026 and Adjusted EBITDA for the full year only, so there is no quarterly guidance to compare with this third quarter release.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readMDXG · second quarter 2026 · ended June 30, 2026

MIMEDX reported second-quarter net sales of $64 million, down 35%, and reiterated 2026 net sales guidance of $260 to $290 million.

→Mixed quarter

Surgical product sales increased 15% year over year and the Company reiterated its full-year outlook, but net sales decreased 35%, gross margin declined to 69%, and the Company reported a $15 million net loss as Medicare reimbursement changes materially affected the Wound business.

Revenue
$64M
a decrease of 35% y/y
Gross margin · GAAP
69%
2026 outlook
$260 to $290 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$64M–a decrease of 35%
Surgical product sales growthother15%–15%
Wound sales declineother61%–a year-over-year decrease of 61%
Gross profitGAAP$44M––
Gross marginGAAP69%––
Selling, general and administrative expensesGAAP$60M––
Research and development expensesGAAP$3M––
Net lossGAAP$15M––
Overall Wound volume growthother22%22%–
Bad debt expense increaseGAAP$5M–increased $5 million, year over year

2026 outlook

  • Revenue$260 to $290 million
  • Note2026 Adjusted EBITDA is expected to approach breakeven on a full year basis.
  • NoteLonger-term, the Company continues to expect to achieve annual net sales growth in the low double-digits with an adjusted EBITDA margin above 20%.

What drove it

  • Surgical product sales increased 15% compared to the prior-year period, led by sales of AMNIOFIX® and AMNIOEFFECT®.
  • Overall Wound volume grew 22% sequentially, with volume in hospital outpatient departments and wound care centers growing at an even higher rate.
  • The cost reduction initiative announced in April and lower commissions on lower sales reduced SG&A expenses.
  • R&D spending reflected ongoing pipeline investments, including costs associated with two 510(k) applications made to the United States Food & Drug Administration.
  • MIMEDX announced a definitive agreement to acquire all outstanding shares of Sanara MedTech Inc. in a cash and stock transaction valued at $35 per Sanara share.

Concerns

  • Several Medicare reimbursement changes effective January 1 negatively affected Wound sales and Wound-product pricing.
  • Gross margin declined due primarily to Medicare reimbursement rules, unfavorable product mix, and other one-time non-recurring expenses connected with cost-reduction actions.
  • Higher bad debt expense reflected credit deterioration of certain legacy customers.
  • Net sales decreased 35% and the Company reported a $15 million net loss.
  • The proposed Sanara transaction remains subject to Sanara shareholder approval, required regulatory approvals, and other customary closing conditions.

What to watch

  • The pace of Wound-business recovery as providers adjust to the reimbursement landscape and new payment structure.
  • Whether Surgical momentum, including AMNIOFIX® and AMNIOEFFECT® sales, continues to offset Wound-business pressure.
  • Progress toward the Company’s stated path back to profitability for the second half of the year and full-year Adjusted EBITDA approaching breakeven.
  • Execution, financing, approvals, and closing of the proposed Sanara acquisition, which is expected to close by the end of the year.

Balance sheet and cash flow

  • As of June 30, 2026, the Company had $136 million of cash and cash equivalents compared to $166 million as of December 31, 2025.
  • As of June 30, 2026, our cash position, net of debt on our balance sheet, was $119 million.
  • MIMEDX expects to finance the cash portion of the Sanara transaction through a combination of cash on hand and a new, committed debt financing in the form of a $300 million term loan.
  • The Sanara transaction has a total enterprise value of approximately $350 million.
  • In connection with definitive debt-financing documentation, MIMEDX’s existing credit agreement will be terminated and all amounts outstanding will be repaid in full.

Analysis

Second-quarter results reflected a sharp divergence between the Company’s Surgical and Wound businesses. Net sales were $64 million, compared with $99 million in the prior-year period, a decrease of 35%. Surgical product sales increased 15% year over year, led by AMNIOFIX® and AMNIOEFFECT®, while Wound sales decreased 61%. Management attributed the Wound decline to Medicare reimbursement changes that became effective on January 1, while also reporting 22% sequential growth in overall Wound volume.

Profitability weakened with revenue and mix. Gross profit was $44 million versus $80 million, while gross margin was 69% compared with 81%. The Company identified lower Wound-product pricing under Medicare reimbursement rules as the primary reason for the quarter-over-quarter gross-margin decline. Unfavorable product mix and one-time non-recurring costs related to cost-reduction actions also contributed.

Expense actions reduced SG&A to $60 million from $64 million, primarily through the April cost-reduction initiative and lower commissions on lower sales. These savings were partly offset by a $5 million year-over-year increase in bad debt expense related to credit deterioration among certain legacy customers. R&D expense was unchanged at $3 million, reflecting pipeline investment and costs related to two 510(k) applications. The Company reported a $15 million net loss, compared with net income of $10 million in the prior-year period.

Liquidity stood at $136 million of cash and cash equivalents as of June 30, 2026, compared with $166 million as of December 31, 2025, and cash net of balance-sheet debt was $119 million. MIMEDX reiterated 2026 net sales guidance of $260 to $290 million and expects full-year Adjusted EBITDA to approach breakeven. Separately, the proposed Sanara acquisition adds a transaction valued at approximately $350 million in enterprise value, with the cash consideration expected to be funded through cash on hand and a committed $300 million term loan.

Management, verbatim

During the second quarter, we delivered another strong performance in our Surgical franchise, with 15% year-over-year revenue growth balanced across our sheet and particulate products.

Joseph H. Capper, MIMEDX Chief Executive Officer

Meanwhile, our Wound business saw positive signs of recovery during the quarter as the industry navigates adjustments in the reimbursement landscape and the resulting implications for patient care.

Joseph H. Capper, MIMEDX Chief Executive Officer

Early in the second quarter, we took swift action to right-size our expense structure for the current market environment, which yielded improving results throughout the quarter, putting us on a path back to profitability for the second half of the year.

Joseph H. Capper, MIMEDX Chief Executive Officer

Not in the filing

stated, not guessed
  • Reported revenue amounts for the Surgical and Wound segments.
  • Operating income or loss.
  • GAAP and non-GAAP earnings per share.
  • Adjusted EBITDA result for the reported quarter.
  • Operating cash flow.
  • Free cash flow.
  • Capital returns, including share repurchases and dividends.
  • Total debt balance as of June 30, 2026.
  • Gross-margin percentage change.
  • Prior-quarter net sales, gross profit, SG&A, R&D, net income or loss, and earnings per share.
  • Prior outlook for comparison with reported results.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about MDXG earnings dates

When is Mimedx Group's next earnings date?
AlphAI has no date for MDXG yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.